By continuing to use this website, you agree to the use of cookies. You can find out more by following this link.

Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}
      • IMPORTANT SAFETY INFORMATION
      RINVOQ (upadacitinib 15mg tablets) logo
      SUMMARY OF PRODUCT CHARACTERISTICS
      IMPORTANT SAFETY INFORMATION
      PRESCRIBING INFORMATION

      RINVOQ is an oral selective and reversible JAK inhibitor indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.

      RINVOQ prescribing guide

      Starting patients on RINVOQ: Helpful information

      This convenient guide  helps educate you on starting patients on RINVOQ, with information on dosing plus screening, monitoring, and safety recommendations.

      Download
      div

      RINVOQ HCP Educational Brochure

      Read this brochure for important safety information on RINVOQ
      div
      div
      SEE SUMMARY OF PRODUCT CHARACTERISTICS
      div
      for more information

      I want to receive more information via a product specialist.

      Go

       

      ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

      This website belongs to internal AbbVie’s initiative and it reflects a possible experience our hcp could have in Abbvie Pro

      Copyright © 2019 AbbVie Inc. SKZD-190010 North Chicago, Illinois, U.S.A.

      Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

      Data of Preparation: September 2019

      Approval code [approvalCode]